Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404283 · ClinicalTrials.gov registry record · Phase 3
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
A Phase 3 study of Diffuse Large B Cell Lymphoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 238
- Enrollment target
- 20
- Study locations
NCT04404283: Active Phase 3 study of Diffuse Large B Cell Lymphoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
NCT04404283 is a Phase 3 study of Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 238 participants, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04404283, a Phase 3 study of Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 238 participants
- Enrollment target
- 20
- Study locations
Study Summary
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.
Primary Outcome
OS is defined as the time from the date of randomization to date of death due to any cause
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Brentuximab vedotin
Study Locations (20)
Florida
- Florida Cancer Specialists - Bonita Springs
- Florida Cancer Specialists - Bradenton
- Florida Cancer Specialists - Cape Coral
- Florida Cancer Specialists - Daytona Beach
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists - Naples
- Florida Cancer Specialists - Port Charlotte
- Florida Cancer Specialists - Sarasota
- Florida Cancer Specialists - Sarasota
- Florida Cancer Specialists - Stuart
- Florida Cancer Specialists - Venice
- Florida Cancer Specialists - Venice
- Florida Cancer Specialists - Vero Beach
- Florida Cancer Specialists - Wellington
- Florida Cancer Specialists - West Palm Beach
California
- University of California Davis Comprehensive Cancer Center - Sacramento
- University of California Davis Medical Center - Sacramento
Alabama
- Central Alabama Research - Birmingham
Kansas
- MidAmerica Division, Inc. c/o Menorah Medical Center - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2020-08-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
What the registry record for NCT04404283 still lists
NCT04404283 is an interventional study that assigns participants to a tested intervention. The registered 238 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT04404283 names 20 study sites across 4 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04404283 about?
NCT04404283 is a clinical study titled "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL". Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assign...
What is the current status of trial NCT04404283?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 238 participants. The study started on 2020-08-20. Estimated completion is 2026-12-31.
What conditions does trial NCT04404283 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT04404283?
The interventions under investigation include: Placebo (OTHER), Rituximab (DRUG), Lenalidomide (DRUG), Brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT04404283?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04404283 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04404283's enrollment target sits among peer trials
238 26th of 114 higher than 89 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RECRUITING · Phase 3
-
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RECRUITING · Phase 3
-
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
- NCT06452797 · 238 participants · NA
Prognostic Estimates Among ICU Clinicians
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI